All In Biotech

Drug Trial Radar · NCT06592664

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 2030

Primary completion

Jan 2035

Study completion Jan 2040

Sponsor

Lead sponsor
Lisata Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment Participants will: * Visit the clinic three times every 28 days for treatment and tests * Have CT or MRI scans every 8 weeks while on treatment

Conditions

  • Pancreas Cancer
  • Pancreatic Carcinoma
  • Pancreas Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Unresectable Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma

Interventions

  • certepetideDrug

    certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given

  • nab-paclitaxelDrug

    nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

  • gemcitabineDrug

    gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

  • placebo matching certepetideDrug

    placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given

  • certepetideDrug

    certepetide given as two IV pushes over 1 minute when standard treatment(s) are given

  • placebo matching certepetideDrug

    placebo given as an IV infusion over 4 hours when standard treatment(s) are given

  • placebo matching certepetideDrug

    certepetide given as a slow IV push over 1 minute when standard treatment(s) are given

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: 30 days after treatment discontinuation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.